SCHEMBL2080129

SCHEMBL2080129

CCOC(=O)N1CCc2[nH]c(=O)cc(Cl)c2CC1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.50
PABPC1 P11940 1/20 0.50
ATM Q13315 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
MAPT P10636 5/20 0.47
MAPK1 P28482 1/20 0.45
HTT P42858 1/20 0.45
TSHR P16473 3/20 0.43
HSD17B10 Q99714 1/20 0.43
KMT2A Q03164 4/20 0.42
MEN1 O00255 2/20 0.42
PKM P14618 1/20 0.42
ALDH1A1 P00352 2/20 0.41
POLB P06746 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
CYP3A4 P08684 1/20 0.41
GRM5 P41594 1/20 0.41
CGAS Q8N884 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2077232 0.86 LMNA (0.51) LMNAPABPC1ATMSMN1; SMN2MAPT
SCHEMBL2080285 0.75 LMNA (0.52) LMNAPABPC1ATMSMN1; SMN2MAPT
SCHEMBL2079525 0.75 LMNA (0.47) LMNAPABPC1ATMSMN1; SMN2MAPT
SCHEMBL15828470 0.73 MAPT (0.46) LMNASMN1; SMN2MAPTMAPK1HTT
SCHEMBL2080394 0.71 LMNA (0.70) LMNAPABPC1ATMSMN1; SMN2MAPT
SCHEMBL7069495 0.71 LMNA (0.49) LMNAPABPC1ATMSMN1; SMN2MAPT
SCHEMBL12868340 0.70 LMNA (0.79) LMNAPABPC1ATMSMN1; SMN2MAPT
SCHEMBL2998360 0.69 ALDH1A1 (0.55) LMNASMN1; SMN2MAPTMAPK1HTT
SCHEMBL1294703 0.69 ADRA2A (0.56) LMNASMN1; SMN2MAPTMAPK1HTT
SCHEMBL2081957 0.69 KDM4E (0.46) SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7897595-B2 Pyridoazepine derivatives FOREST LABORATORIES HOLDINGS LIMITED (BM) 2011-03-01 US claimed
WO-2007140213-A1 PYRIDOAZEPINE DERIVATIVES FOREST LABORATORIES HOLDINGS LIMITED (BM) 2007-12-06 WO claimed
US-20070281918-A1 PYRIDOAZEPINE DERIVATIVES FOREST LABORATORIES HOLDINGS LIMITED (BM) 2007-12-06 US claimed
US-7897595-B2 Pyridoazepine derivatives FOREST LABORATORIES HOLDINGS LIMITED (BM) 2011-03-01 US disclosed
WO-2007140213-A1 PYRIDOAZEPINE DERIVATIVES FOREST LABORATORIES HOLDINGS LIMITED (BM) 2007-12-06 WO disclosed
US-20070281918-A1 PYRIDOAZEPINE DERIVATIVES FOREST LABORATORIES HOLDINGS LIMITED (BM) 2007-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281918-A1 PYRIDOAZEPINE DERIVATIVES HTR2C, HTR5A, HTR2A LMNA 1039/4885PABPC1 3444/4885ATM 4119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.